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Original Articles
Inhibition of Pancreaticobiliary Secretion by Loperamide 
in Humans
P aul  W . L. T h im ister ,1 W im  P. M. H o p m a n ,1 Ro l f  F. C. v a n  Ro e r m u n d ,1 H ans L. W illem s ,2 G erd  Ro sen bu sch ,
R o b er t  W o e st e n b o r g h s  4 a n d  J a n  B. M . J . J a n se n 1
Loperamide, a peripherally acting opiate receptor agonist 
with antidiarrheal action, inhibits ileal and colonic motor 
function. It was determined whether loperamide also affects 
gallbladder emptying and pancreatic enzyme secretion in hu­
mans. Plasma cholecystokinin (radioimmunoassay), gallblad­
der volume (ultrasonography), and intraduodenal bilirubin 
and amylase output (spot sampling) were measured at regular 
intervals before and during intraduodenal perfusion of an 
amino acid meal in 8 healthy subjects: once without and once 
with pretreatment of 8 mg loperamide, ingested 13 and 4 
hours before the start of the meal. Loperamide decreased 
basal amylase output from 3.2 ±  0.5 to 1.0 ±  0.5 kU/h 
(P <  ,005) and abolished basal bilirubin output (21 ±  5 vs. 
0 ±  0 ¿¿mol/h; P <  .005) into the duodenum. Loperamide 
increased basal gallbladder volume from 28 ±  4 to 39 ± 4  
mL (P <  .0001) but was without effect on basal plasma 
cholecystokinin (2.7 ± 0.3 vs. 3.0 ±  0.3 pmol/L). During 
the amino acid meal, pretreatment with loperamide inhibited 
amylase output from 5.1 ±  0.8 to 1.6 ±  0.4 kU/h (P <  .001), 
bilirubin output from 39 ± 6  to 18 ± 6  ¿¿mol/h (P <  .0005) 
and gallbladder contraction from 47% ± 3% to 26% ±  6% 
(P <  .05), whereas loperamide enhanced amino acid-stim u- 
lated plasma cholecystokinin from 4.5 ±  1.6 to 7.6 ±  1.0 
pmol/L (P <  .05). It is concluded that loperamide inhibits 
basal and amino acid-stimulated gallbladder motility and 
intraduodenal output of bilirubin and amylase, despite an 
enhanced postprandial cholecystokinin release. (H e p a t o l -
o g y  1997;26:256-261.)
Loperamide is widely used for the treatment of patients 
with diarrhea resulting from a variety of diseases.1,2 Dosages 
used to treat acute or chronic diarrhea vary from 2 to 16 mg 
daily.1 Recently, even higher dosages have been recom- 
mended. Loperamide probably exerts its antidiarrheal action 
by a change in motor function of the intestine, resulting in 
an increased capacitance of the gut and a delay in the passage 
of fluid through the intestine.1,3 Some studies also suggest 
antisecretory effects of the drug at the intestinal level.4,5 The
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effects of loperamide on pancreaticobiliary functions are 
poorly investigated. Inhibition of gallbladder emptying or 
pancreatic enzyme secretion by loperamide may have im­
portant clinical implications because stasis of bile is a major 
factor contributing to the formation of gallstones6'10 and be­
cause impairment of pancreatic enzyme secretion may induce 
or aggravate maldigestion.11-13
The aim of this study, therefore, was to determine the 
effect of loperamide on basal and meal-stimulated gallbladder 
motility and pancreatic enzyme secretion in healthy volun­
teers. Gallbladder emptying and pancreatic enzyme secretion 
were studied in response to an intraduodenal amino acid 
meal to circumvent possible influences of loperamide on gas­
tric emptying or on the digestion of nutrients.14
PATIENTS AND METHODS
Subjects. Eight healthy volunteers (3 w om en and 5 men; age 
range, 19-27 years) participated in the studies. None of the volun­
teers was taking any medication or had  a history of gastrointestinal 
sym ptom s or surgery. The study protocol was approved by the 
ethical com m ittee of the University Hospital Nijmegen, and all sub­
jects gave their written informed consent before entering the study.
Reagents. Loperamide chloride was obtained from Janssen Phar­
maceutica (Beerse, Belgium). Radioiodinated porcine pancreatic 
polypeptide was obtained from Novo N ordisk AS (Bagsvaerd, Den­
m ark). Synthetic CCK33 was from Peninsula Laboratories Europe,
j  ^  ^  ■
Ltd. (St. Helens, England). I-hydroxyphenyl propionic acid-suc- 
cinimide ester (Bolton-Iiunter reagent) was obtained from New 
England N uclear Corp. (Boston, MA). Pharmacia Decanting Suspen­
sion no. 3 was from Pharmacia Diagnostics, AB (Uppsala, Sweden). 
H um an pancreatic polypeptide and L-amino acids were from Sigma 
Chemical Co. (St. Louis, MO). Polyethylene glycol 4000 (PEG- 
4000) from  BDH, Ltd. (Poole, England). All other materials were 
obtained from  Merck (Amsterdam, The Netherlands).
S itu iy Protocol After a 12-hour fast, the volunteers presented at 
the laboratory at 7:30 am. In random  order, two experiments were 
perform ed separated from each other by at least 1 week. At the 
beginning of each test a double-lum en polyvinyl tube with an OD 
of 5.7 m m  was placed in the duodenum . The proximal lumen of 
the tube was positioned at the level of the papilla Vateri, and the 
distal lum en was positioned at the ligam ent of Treitz. The position 
of the tube was verified by fluoroscopy. In addition, an in-dwelling 
intravenous catheter was placed in a forearm. The catheter was kept 
paten t by a heparine-saline solution and was used for the collection 
of blood samples. After an equilibration period of at least 30 m in­
utes, the following tests were performed. In  test 1, saline (300 
mosmol/L) was continuously perfused intraduodenally for 2 hours 
(300 mL/h) together with the recovery m arker PEG-4000 (6g/L). 
D uring the third  test hour, an isoosmotic solution (300 mOsm; Fig. 
1) of an amino acid m ixture,15 containing L-valine (2.17 g), L- 
m ethionine (1.7 1 g), L-tryptophan (0.67 g), and L-phenylalanine 
(2.34 g) was perfused intraduodenally together with saline (140
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F ig . 1. Study protocol for the two tests performed in random order. In 
both tests, saline was continuously perfused intraduodenally together with 
the recovery marker PEG-4000 (1,8 g/li) from —60 to 120 minutes at a 
constant rate of 5 mL/h. During the last test hour, 6.89 g of an amino 
acid solution was also perfused intraduodenally. In one of the two tests* 
loperamide (8 mg) was ingested 13 and 4 hours before the start of the amino 
acid perfusion. *Time points when blood was drawn for the measurement of 
plasma CCK and pancreatic polypeptide levels, whereas gallbladder volume 
was determined by ultrasonography. +Time points when duodenal juice was 
sampled for the determination of bilirubin and amylase.
mL) and demineralized w ater (160 mL). Test 2 was perform ed 
according to the same protocol as test 1. However, 13 and 4 h o u rs  
before the start of the amino acid perfusion, 8 m g of loperam ide 
was administered orally (Fig. 1). Five-milliliter samples of duodenal 
contents were taken during 15-minute periods from the tip o f  the 
tube by spot-sampling16 and kept on ice. Blood samples were taken  
every 30 minutes during the first hour and subsequently every 15 
minutes until the end of the test period (Fig. 1).
Blood was collected into ice-chilled glass tubes containing 2 g/L 
of ethylenediaminetetraacetic acid. After the experiments, the b lo o d  
samples were centrifuged at 4°C for 15 m inutes (3,000g). In test 2, 
an additional blood sample was taken just before the s ta rt o f the  
amino acid perfusion for m easurem ent of plasma loperam ide levels. 
Plasma and duodenal samples were stored at —20°C until assayed 
for cholecystokinin (CCK), pancreatic polypeptide, loperam ide, 
PEG-4000, bilirubin, and amylase. Each time that a blood sam ple 
was taken, two longitudinal and two transverse images of the gall­
bladder were obtained by real-time ultrasonography.
Plasma Samples. Plasma CCK was measured by a sensitive and  
specific radioimmunoassay as described previously.17,18 The an ti­
body used (T204) binds to biologically active CCK peptides co n ­
taining the sulfated tyrosine region with almost equal affinity. O n  
a molar base, sulfated gastrins cross-reacted <2%  in the assay, 
whereas no cross-reactivity with unsulfated gastrins or s tructu ra lly  
unrelated peptides was found. The detection limit of the assay was 
between 0.5 and 1.0 pmol/L CCK in plasma. The intra-assay p rec i­
sion ranged from 4.6% to 11.5% in the steep part o f the s tandard  
curve. All m easurements of plasma CCK levels were perform ed in  
the same run.
Plasma pancreatic polypeptide levels were also determ ined by  
radioimmunoassay.19 The antibody used showed no cross-reactivity 
with struc tur ally related gastrointestinal regulatory peptides, such  
as peptide YY or neuropeptide Y, or with structurally u n re la ted  
peptides. The detection lim it of the assay was 0.5 pmol/L of in cu b a ­
tion mixture. The intra-assay variation ranged from  4% to 7% in  
the steep part of the standard curve. All m easurem ents of plasm a 
pancreatic polypeptide levels were performed in one run.
Plasma loperamide levels were determined at the departm ent of 
Drug, Metabolism and Pharmacokinetics, Janssen Pharm aceutica, 
Beerse, Belgium, as described previously.20
Duodenal Samples. Duodenal samples were analyzed for PEG- 
4000,21 bilirubin,22 and amylase activity.23 Flow rates passing the
distal duodenal sam pling site w ere calculated based on know n per­
fusion rates and  PEG-4000 concen tra tions a t the perfusion and 
sam pling p o rts .16 O utpu ts  of b ilirub in  and  amylase were calculated 
from the p ro d u c t of concen tra tions o r activity and  flow rates.
Gallbladder Ultrasonography. L ongitudinal and transverse images 
of the gallbladder were ob tained  by real-tim e ultrasonography (So- 
nolayer Sal 77-B; Toshiba, Tokyo, Japan) using a 3.75-MHz trans­
ducer.24,25 Gallbladder vo lum e was calculated from  these images by 
the sum  of cylinders m eth o d  using  a com puter system.26 The varia­
tion of volum e m easurem ents ranged  from  6% to 22%.
Statistical Analysis. All m easurem ents were perform ed in dupli­
cate, and  the m ean  of these two m easurem ents was used for further 
analysis of results. G allbladder volum e w as expressed in  milliliters 
and as percentage of the m ean basal value at 45 and 60 m inutes. 
Integrated plasm a CCK, pancreatic  polypeptide, and gallbladder 
responses were determ ined by calculating the area under the plasma 
CCK concentration-tim e curves, pancreatic  polypeptide concentra­
tion-tim e curves, or gallbladder volum e time curves. Subsequently, 
increm ental plasm a CCK, pancreatic  polypeptide concentrations, 
and gallbladder volum e responses to the meal were calculated by 
subtracting the in tegrated response in  the basal period (0-60 m in­
utes) from  the in tegrated  response in the period  of stim ulation (60- 
120 m inutes) in each experim ent. Similarly, increm ental bilirubin 
and amylase ou tpu ts w ere calculated by subtraction o f the total 
ou tpu t in the basal period  (0-60 m inu tes) from the total ou tpu t in 
the period  of stim ulation  (60-120 m inutes). Results are expressed 
as m eans ±  SEM. Statistical analysis was perform ed by Student’s £ 
test for p a ir e d . results or by two-way analysis of variance w hen 
appropriate. Differences w ith  a tw o-tailed P value of .05 were con­
sidered significant.
RESULTS
Plasma Loperamide Levels. Plasma levels of loperamide at 
the start of the amino acid perfusion in test 2 were 2.5 ± 
0.3 ng/mL
Plasma Concentrations of CCK and Pancreatic Polypep­
tide. Plasma CCK and pancreatic polypeptide time curves are 
shown in Figs. 2 and 3. Loperamide significantly (P <  .05) 
inhibited basal pancreatic polypeptide levels from 25 ± 5 to 
20 ±  4 pmol/L (Fig. 3 and Table 1) but was without signifi­
cant effect on basal CCK (2.7 ±  0.3 pmol/L without lopera­
mide vs. 3.0 ±  0.3 pmol/L with loperamide; Fig. 2 and Table
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F ig . 2. Basal and amino acid-stimulated plasma CCK concentrations 
(in pmol/L) in 8 healthy subjects with ( • )  or without (O) prior ingestion 
of loperamide. Values are expressed as means ±  SEM.
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Fig. 3. Basal and amino acid-stimulated plasma pancreatic polypeptide 
concentrations (in pmol/L) in 8 healthy subjects with ( • )  or without (O) 
prior ingestion of loperamide. Values are expressed as means ±  SEM.
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Fig, 4. Basal and amino acid-stimulated gallbladder volume (in mL) 
in 8 healthy subjects with ( • )  or without (O) prior ingestion ofloperamide. 
Values are expressed as means ± SEM.
1). Intraduodenal administration of the amino acid meal in­
duced a significant (P <  .05) increase of plasma pancreatic 
polypeptide from 25 ± 5 to 36 ±  7 pmol/L (Fig. 3) and of 
plasma CCK from 2.7 ±  0.3 to 4.5 ±  1.6 pmol/L (Fig. 2). 
Loperamide induced a statistically significant (P <  ,05) en­
hancement of the amino acid-stim ulated plasma CCK level 
from 4.5 ±  1.6 to 7.6 ±  1.0 pmol/L (Fig. 2 and Table 1) but 
inhibited (P <  .05) amino acid-stim ulated plasma pancre­
atic polypeptide levels from 36 ±  7 to 28 ± 7 pmol/L (Fig.
3 and Table 1).
Gallbladder Volume and Bilirubin Output. After pretreatment 
with loperamide, basal gallbladder volume was significantly 
greater than in the control experiment (39 ±  4 mL vs. 28 ±
4 mL; P <  .0001; Fig. 4 and Table 1). This increase in 
gallbladder volume was accompanied by complete inhibition 
of bilirubin output into the duodenum under basal condi­
tions (Fig, 5 and Table 1). Intraduodenal perfusion of amino 
acids resulted in significant gallbladder contraction (P <  
.0001) and bilirubin output (P <  .01) into the duodenum 
(Fig. 4 and Table 1). Loperamide significantly (P <  .05) 
attenuated maximum gallbladder contraction in response to
the amino acid meal from 47% ± 3% to 26% ± 6% (Fig. 4 
and Table 1) and intraduodenal bilirubin output from 39 ± 
6 to 18 ±  6 jumol/h (P <  .0001; Fig. 5 and Table 1).
Pancreatic Enzyme Output. Loperamide inhibited basal amy­
lase output from 3.2 ± 0,5 to 1.0 ±  0.5 kU/h (P <  .005) 
and amino acid stimulated output from 5.1 ±  0.8 to 1.6 ± 
0.4 kU/h (P <  .001; Fig. 6 and Table 1).
DISCUSSION
Loperamide is a synthetic opiate receptor agonist that se­
lectively interacts with peripheral opiate receptors in the di­
gestive tract.1,27'29 Enkephalins are natural ligands for these 
receptors. Enkephalins have not only been shown in the 
colon, where loperamide competes with these ligands to in­
hibit bowel movements, but also in other places of the diges­
tive system, such as the gastric antrum, duodenum, pancreas, 
cystic duct, and bile duct.27,30 The results of the present study 
(with the administration of loperamide causing plasma levels 
in the therapeutical range1) provide evidence that loperamide 
not only interacts with peripheral opiate receptors in the 
colon but also with opiate receptors in the proximal part of
Table 1. Integrated Responses
Test Basal (0-60 min) Amino Acids (60-120 min) Incremental
CCK (pmol/L • 60 min) Without loperamide 174 ±  24 229 ± 55 55 ± 35
With loperamide 181 ±  18 411 ±  52* 230 ± 41*
PP (pmol/L • 60 min) Without loperamide 1,606 ±  279 1,886 ±  384 280 ± 130
With loperamide 1,258 ±  220* 1,446 ±  295* 188 ± 109
Gallbladder volume (mL * 60 min) Without loperamide 1,619 ±  219 1,198 ±  193 -421 ± 56
With loperamide 2,209 ±  208* 2,077 ± 223* -132 ± 76*
Bilirubin (/¿mol) Without loperamide 21 ±  5 39 ± 6 18 ± 5
With loperamide 0 ±  0* 18 ± 6* 18 ± 6
Amylase (kU) Without loperamide 3.2 ±  0.5 5.1 ±  0.8 1.9 ± 0.6
With loperamide 1.0 ±  0.5* 1.6 ±  0.4* 0.5 ± 0.3
NOTE. Integrated responses under basal conditions (0-60 min) and in response to amino acids (60-120 min) in 8 healthy subjects with or without 
loperamide pretreatment. Incremental responses were obtained after subtraction of integrated values in the basal period (0-60 min) from integrated values 
during the period of stimulation (60-120 min). Results are expressed as means ±  SEM.
Abbreviation: PP, pancreatic polypeptide.
* Significantly different from test without loperamide pretreatment (P <  .05).
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F ig .  5. Basal and amino acid-stimulated bilirubin output (in /¿mol/15 
min) in 8 healthy subjects with ( • )  or without (O) prior ingestion of 
loperamide. Values are expressed as means ± SEM.
the intestinal tract, because we have found that loperamide 
inhibits basal and amino acid—stimulated gallbladder motil­
ity and bilirubin output, as well as amylase output.
Several studies show that ultrasonography and the sum of 
cylinders method is a reliable, accurate, and precise method 
for quantification of gallbladder volume and gallbladder con­
traction in humans. 6,31-34 However, it has to be noted that 
the changes in gallbladder volume as measured by ultraso­
nography do not necessarily reflect the total amount of bile 
em ptied from the gallbladder. The gallbladder probably does 
not em pty in a steady progressive fashion in response to a 
meal, b u t filling and emptying occur more or less simultane­
ously.35"37 Jazrawi et al. provided evidence that refilling of 
the gallbladder starts immediately after the ingestion of a 
meal and that the total volume of bile expelled by the gall­
bladder postprandially amounts to up to six times its basal 
volum e.36 They argued that the majority of hepatic bile enters 
the gallbladder before reaching the duodenum even in the 
postprandial period.35,36 This indicates that the cumulative 
b ilirubin  output into the duodenum may be a good estimate 
of the total amount of bile handled by the gallbladder. The 
data of the present study indicate that loperamide potently 
inhibited gallbladder motor function as measured both by 
ultrasonography and by intraduodenal bilirubin output.
In a previous study, it was shown that loperamide inhibited 
basal and meal-stimulated trypsin and bilirubin output into 
the duodenum  of patients with a short bowel syndrome.38 
From  that study, it was not clear whether loperamide inhib­
ited these functions by inhibition of gastric emptying 39 re­
sulting in a diminished supply of food to stimulating recep­
tors for gallbladder contraction and pancreatic enzyme 
secretion in the duodenum. To exclude effects of loperamide 
on gastric emptying, we administered the test meal into the 
duodenum . An elementary test meal was used to exclude 
possible confounding effects of loperamide on nutrient diges­
tion, because we have shown previously that appropriate 
digestion of protein is essential for stimulation of CCK re­
lease and pancreaticobiliary secretion in humans.14
It has been suggested that the inhibitory effect of the opioid 
peptide enkephalin on meal-stimulated pancreatic protein 
secretion in dogs was mediated by a reduction in the release
of CCK.40,41 According to our data, the evidence in humans 
is otherwise because the release of CCK in response to a 
meal is enhanced by loperamide. A prolonged contact time 
between stimulating nutrients and CCK-secreting cells may 
be I'esponsible for this enhanced release of CCK by lopera­
mide because loperamide delays the passage of fluid through 
the intestine. In a previous study, we have shown that lopera­
mide inhibits gallbladder contraction in response to intrave­
nously administered CCK, resulting in plasma CCK concen­
trations as observed after a meal.42 We therefore postulate 
that the sensitivity of the pancreas and gallbladder to respond 
to an amino acid meal (causing increases of CCK in the 
physiological range as observed postprandially) is attenuated 
by loperamide because of interference with opioid receptors 
on the pancreas and gallbladder. Subsequently, according 
to the negative feedback concept between pancreaticobiliary 
output and CCK release,43'46 the diminished output of pan­
creaticobiliary products into the duodenum enhances the 
release of CCK.
Recently, it was shown that enkephalin attenuates pancre­
atic enzyme secretion in the rat by inhibiting the release of 
acetylcholine.47 A direct effect of opioids on pancreatic acini 
was unlikely.48 In humans, loperamide may also attenuate 
pancreaticobiliary secretion by inhibiting the release of ace­
tylcholine. The finding of decreased pancreatic polypeptide 
levels, a hormone that is primarily controlled cholinergi- 
cally,49,30 after administration of loperamide supports the hy­
pothesis that loperamide also interferes with the human cho­
linergic system to attenuate pancreaticobiliary secretion.
The results of the present study may also be explained by 
an increased outflow resistance at the level of the sphincter 
of Oddi.51,52 However, this is unlikely because basal amylase 
output was not inhibited, and amino acid-stimulated amy­
lase and bilirubin output were not abolished.
A diminished gallbladder motility causes bile stasis, which is 
a major factor contributing to the formation of gallstones.6'10 
Therefore, it may be speculated that patients undergoing 
long-term treatment with loperamide are at risk for the devel­
opment of gallstone disease. The finding that loperamide also 
increased the cholesterol saturation index of bile in normal 
volunteers who took loperamide capsules sufficient to cause
Eto
2~
zs
Q.
3O
a></>
iS
E
<
1
0
0 30 60
Time (min)
90 120
Fig. 6. Basal and amino acid-stimulated amylase output (in kU/15 
min) in 8 healthy subjects with ( • )  or without (O) prior ingestion of 
loperamide. Values are expressed as means ±  SEM.
260 THIMISTER ET AL. H e p a t o l o g y  August 1997
symptomatic constipation and slowing down of small intesti­
nal transit supports this notion,53 However, we are not aware 
of any study dealing with the incidence of gallstone disease 
in patients undergoing long-term treatment with loperamide.
The finding that the short-term administration of lopera­
mide impairs pancreatic enzyme secretion in healthy subjects 
may also have clinical implication. As far as we know, there is 
one study in humans that showed an inhibition of pancreatic 
enzyme secretion by loperamide in patients with a short 
bowel syndrome.38 Although loperamide is generally consid­
ered a safe drug, with few adverse reactions reported world­
wide,54,55 further studies are needed to determine the clinical 
relevance of the inhibitory effects of loperamide on gallblad­
der motility and pancreatic enzyme secretion, particularly in 
patients undergoing long-term treatment with higher doses.
In conclusion, loperamide inhibits basal and amino acid- 
stimulated gallbladder motility and pancreatic enzyme secre­
tion in humans, despite an enhanced amino acid—stimulated 
CCK release.
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